Company intelligence / Profile preview

Assertio

Lake Forest, Illinois, United States

Ownership: Public · ASRT
Employees: ~58
Development stage: Other

Overview

Assertio commercializes a portfolio of FDA-approved prescription drugs, including NSAIDs for pain and migraine (Cambia, Zipsor), and via its 2023 Spectrum Pharmaceuticals acquisition, ROLVEDON for chemotherapy-induced neutropenia. Assertio’s legacy neurology/pain franchises have generated stable revenues, but recent growth is driven by business development and oncology entry.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeSynthetic glucocorticoid corticosteroidBiologic
Industry: Biotech

Drug pipeline

19 assets

fluorouracil

Approved

18 more assets in the full pipeline.

Request access →

Partnerships

Collegium Pharmaceutical

Beyond the preview

Go deeper on Assertio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Assertio.

Explore the full profile